Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPDAPT-2 ACS
jRCTs052180193Completed
- Sponsor
- Abbott Laboratories
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised trial of clopidogrel in coronary arteriosclerosis, stable angina, myocardial infarction (MI) and 1 more (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Primary composite endpoint at 12 months and Primary composite endpoint at 60 months. Started Mar 2018; status: completed.
02
Drugs
clopidogrel
03
Conditions
coronary arteriosclerosisstable anginamyocardial infarction (MI)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on jRCTs052180193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs052180193.